BioSpace News Archive

Enzolytics, Inc. announced that the Company’s wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.

DiaMedica Therapeutics Inc. announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th.

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD.

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced its participation in three upcoming conferences during the month of May.

Singlera Genomics today announced that it had received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its PDACatch assay, a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.

Baxter International Inc., a leading global medtech company, announced that it has signed a definitive agreement to divest its BioPharma Solutions business to Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor.